AU2019335968B2 - Heterocyclic compound - Google Patents
Heterocyclic compound Download PDFInfo
- Publication number
- AU2019335968B2 AU2019335968B2 AU2019335968A AU2019335968A AU2019335968B2 AU 2019335968 B2 AU2019335968 B2 AU 2019335968B2 AU 2019335968 A AU2019335968 A AU 2019335968A AU 2019335968 A AU2019335968 A AU 2019335968A AU 2019335968 B2 AU2019335968 B2 AU 2019335968B2
- Authority
- AU
- Australia
- Prior art keywords
- mhz
- nmr1
- ring
- compound
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2024203760A AU2024203760A1 (en) | 2018-09-07 | 2024-06-04 | Heterocyclic compound |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018167488 | 2018-09-07 | ||
| JP2018-167488 | 2018-09-07 | ||
| PCT/JP2019/035233 WO2020050409A1 (en) | 2018-09-07 | 2019-09-06 | Heterocyclic compound |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024203760A Division AU2024203760A1 (en) | 2018-09-07 | 2024-06-04 | Heterocyclic compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019335968A1 AU2019335968A1 (en) | 2021-05-06 |
| AU2019335968B2 true AU2019335968B2 (en) | 2024-03-07 |
Family
ID=68063002
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019335968A Active AU2019335968B2 (en) | 2018-09-07 | 2019-09-06 | Heterocyclic compound |
| AU2024203760A Pending AU2024203760A1 (en) | 2018-09-07 | 2024-06-04 | Heterocyclic compound |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024203760A Pending AU2024203760A1 (en) | 2018-09-07 | 2024-06-04 | Heterocyclic compound |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11932657B2 (enExample) |
| EP (1) | EP3847176A1 (enExample) |
| JP (1) | JP7448527B2 (enExample) |
| KR (1) | KR102810086B1 (enExample) |
| CN (1) | CN112654627A (enExample) |
| AU (2) | AU2019335968B2 (enExample) |
| CA (1) | CA3109610A1 (enExample) |
| EA (1) | EA202190654A1 (enExample) |
| IL (1) | IL280821B2 (enExample) |
| SG (1) | SG11202101963XA (enExample) |
| TW (1) | TWI854995B (enExample) |
| WO (1) | WO2020050409A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102810086B1 (ko) | 2018-09-07 | 2025-05-21 | 오츠카 세이야쿠 가부시키가이샤 | 헤테로시클릭 화합물 |
| WO2021117733A1 (en) | 2019-12-09 | 2021-06-17 | Otsuka Pharmaceutical Co., Ltd. | Acrylamide compounds |
| KR20220153595A (ko) | 2020-02-26 | 2022-11-18 | 재규어 테라퓨틱스 피티이 리미티드 | AhR 신호전달의 조절에 유용한 피리도피리미딘 유도체 |
| CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
| CN115215720B (zh) * | 2021-04-19 | 2023-08-22 | 中国科学院化学研究所 | 含薁单元的石墨烯纳米片段分子—薁并玉红省及其合成方法与应用 |
| WO2022228399A1 (zh) * | 2021-04-27 | 2022-11-03 | 山东轩竹医药科技有限公司 | 三并环类usp1抑制剂及其用途 |
| WO2023033741A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| WO2023033742A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| US20250129092A1 (en) * | 2021-09-02 | 2025-04-24 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| CN119948035A (zh) | 2022-10-03 | 2025-05-06 | 捷豹治疗有限公司 | 可用于调节AhR信号传导的化合物 |
| CN120187915A (zh) * | 2022-10-29 | 2025-06-20 | 松本油脂制药株式会社 | 弹性纤维用处理剂及其利用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014138485A1 (en) * | 2013-03-08 | 2014-09-12 | Irm Llc | Ex vivo production of platelets from hematopoietic stem cells and the product thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| AU2011343712B2 (en) * | 2010-12-16 | 2015-09-17 | Genentech, Inc. | Tricyclic PI3k inhibitor compounds and methods of use |
| HK1248762A1 (zh) | 2015-06-16 | 2018-10-19 | 国立大学法人京都大学 | 高功能性血小板的制造方法 |
| FI3612030T3 (fi) | 2017-04-21 | 2026-03-20 | Pahr Therapeutics Inc | Ahr:n indoliestäjiä ja niiden käyttötapoja |
| WO2019167973A1 (en) | 2018-03-01 | 2019-09-06 | Kyoto University | Cell cycle progression inhibitor |
| KR102810086B1 (ko) | 2018-09-07 | 2025-05-21 | 오츠카 세이야쿠 가부시키가이샤 | 헤테로시클릭 화합물 |
| WO2021117733A1 (en) | 2019-12-09 | 2021-06-17 | Otsuka Pharmaceutical Co., Ltd. | Acrylamide compounds |
| JP2022188761A (ja) | 2021-06-09 | 2022-12-21 | 大塚製薬株式会社 | 窒素原子含有複素環化合物を用いる血小板産生方法 |
-
2019
- 2019-09-06 KR KR1020217009658A patent/KR102810086B1/ko active Active
- 2019-09-06 WO PCT/JP2019/035233 patent/WO2020050409A1/en not_active Ceased
- 2019-09-06 AU AU2019335968A patent/AU2019335968B2/en active Active
- 2019-09-06 EP EP19773956.8A patent/EP3847176A1/en active Pending
- 2019-09-06 EA EA202190654A patent/EA202190654A1/ru unknown
- 2019-09-06 SG SG11202101963XA patent/SG11202101963XA/en unknown
- 2019-09-06 JP JP2021512830A patent/JP7448527B2/ja active Active
- 2019-09-06 TW TW108132216A patent/TWI854995B/zh active
- 2019-09-06 CN CN201980058108.7A patent/CN112654627A/zh active Pending
- 2019-09-06 US US17/271,479 patent/US11932657B2/en active Active
- 2019-09-06 CA CA3109610A patent/CA3109610A1/en active Pending
- 2019-09-06 IL IL280821A patent/IL280821B2/en unknown
-
2024
- 2024-01-18 US US18/416,261 patent/US20240208999A1/en active Pending
- 2024-06-04 AU AU2024203760A patent/AU2024203760A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014138485A1 (en) * | 2013-03-08 | 2014-09-12 | Irm Llc | Ex vivo production of platelets from hematopoietic stem cells and the product thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EA202190654A1 (ru) | 2021-05-27 |
| WO2020050409A1 (en) | 2020-03-12 |
| TW202035423A (zh) | 2020-10-01 |
| NZ774547A (en) | 2025-10-31 |
| US11932657B2 (en) | 2024-03-19 |
| JP2021536482A (ja) | 2021-12-27 |
| CA3109610A1 (en) | 2020-03-12 |
| AU2019335968A1 (en) | 2021-05-06 |
| US20210340157A1 (en) | 2021-11-04 |
| IL280821A (en) | 2021-04-29 |
| KR20210056373A (ko) | 2021-05-18 |
| TWI854995B (zh) | 2024-09-11 |
| US20240208999A1 (en) | 2024-06-27 |
| IL280821B2 (en) | 2025-02-01 |
| AU2024203760A1 (en) | 2024-06-20 |
| KR102810086B1 (ko) | 2025-05-21 |
| CN112654627A (zh) | 2021-04-13 |
| SG11202101963XA (en) | 2021-03-30 |
| EP3847176A1 (en) | 2021-07-14 |
| IL280821B1 (en) | 2024-10-01 |
| JP7448527B2 (ja) | 2024-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024203760A1 (en) | Heterocyclic compound | |
| TWI801372B (zh) | 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法 | |
| CN101835764B (zh) | 唑甲酰胺化合物或其盐 | |
| US12441703B2 (en) | Carboxamides as modulators of sodium channels | |
| AU2002219555B2 (en) | VLA-4 Inhibitors | |
| JP3614865B2 (ja) | 新規な環状ジアミン化合物及びこれを含有する医薬 | |
| TWI440639B (zh) | 作為ｔｒｐｖ１調節劑之四氫-嘧啶并氮呯類 | |
| TWI836960B (zh) | 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法 | |
| CA2735730A1 (en) | 2,4-diaminopyrimidine compound | |
| CA2793856A1 (en) | Tetrahydrobenzothiophene compound | |
| AU2023254325A1 (en) | Kif18a inhibitor and use thereof | |
| CN106458940A (zh) | 人类免疫缺陷病毒复制的抑制剂 | |
| JP2016510781A (ja) | ＲＯＲｃモジュレーターとしてのアリールスルファミド及びスルファミン酸誘導体 | |
| WO2009085256A1 (en) | Anti-hiv compounds | |
| CA2761853A1 (en) | Benzoxazolone derivatives as aldosterone synthase inhibitors | |
| JP2016502987A (ja) | ＲＯＲｃモジュレーターとしてのベンジルスルホンアミド誘導体 | |
| KR20180040560A (ko) | Ror 감마 (rory) 조정제 | |
| JP2007145828A (ja) | 医薬組成物 | |
| WO2010102154A2 (en) | Biaryl oxyacetic acid compounds | |
| CN112469714B (zh) | 作为端锚聚合酶抑制剂的1,2,4-三唑衍生物 | |
| CA3155466A1 (en) | Acrylamide compounds | |
| WO2004112709A2 (en) | Inhibitors of cathepsin s | |
| EA046483B1 (ru) | Гетероциклическое соединение | |
| HK40048052A (zh) | 杂环化合物 | |
| AU2013351550A1 (en) | Specific carboxamides as KCNQ2/3 modulators |